Non-coding RNA profiling in BRAFV600E-mutant cutaneous melanoma before and after Spry1 depletion

Cutaneous melanoma (CM), with a continuously rising incidence worldwide, represents the most aggressive type of skin cancer, and it leads to the majority of skin cancer-related deaths. Approximately 50% of CM carry the activating BRAF^V600 mutation and, although BRAF inhibitors have demonstrated clinical efficacy, most patients often develop early resistance to treatment. Aberrant expression of non-coding RNAs (ncRNAs), which represent less than 2% of the entire transcriptome, has been implicated in CM development and progression. By using BRAF^V600-mutant CM in vitro and in vivo models, we have recently demonstrated that the loss of Spry1 expression impairs BRAF^V600-mutant CM progression. Therefore, the extensive long and small ncRNA datasets generated in this study might represent a valuable resource for the characterization of their roles in BRAF^V600-mutant CM initiation and progression upon Spry1 loss, thus providing a comprehensive resource to support future studies on BRAF^V600-mutant CM.